Oculus Innovative SC (OCLS) 4.32 $OCLS
Oculus Innovative Sciences Announces Record Monthly and Quarterly Prescription Data
GlobeNewswire - Wed Jul 06, 3:05AM CDT
May 2016: Highest Monthly Prescriptions Filled in Oculus' History
OCLS: 4.32 (-0.06)
SECFilings.com Examines Oculus Innovative Sciences' Financial Results and Turnaround Plan
Marketwire Canada - Mon Jun 27, 8:39AM CDT
REDONDO BEACH, CA--(Marketwired - Jun 27, 2016) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, takes a look at Oculus Innovative Sciences' (NASDAQ: OCLS) recently announced fourth quarter and fiscal year 2016 results, as well as the company's ambitious turnaround plan.
OCLS: 4.32 (-0.06)
Oculus Innovative Sciences Announces Reverse Split of Common Stock
GlobeNewswire - Wed Jun 22, 4:05AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ: OCLS, warrants OCLSW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, announced today that a 1-for-5 reverse split of its common stock will be effective after the close of business on Friday, June 24, 2016. The reverse stock split was previously approved by the company's stockholders at the company's special meeting held on June 29, 2015. The company's board of directors approved the implementation of a reverse stock split and determined the appropriate reverse stock split to be a ratio of 1-for-5 on June 2, 2016. The reverse split was not the result of any NASDAQ actions.
OCLS: 4.32 (-0.06)
Oculus Innovative Sciences Announces Financial Results for the Fiscal Year/Fourth Quarter 2016 and Conference Call
GlobeNewswire - Thu Jun 02, 3:05AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ: OCLS, warrants OCLSW), today announced that the financial results for its fiscal year and fourth quarter 2016, ended March 31, 2016, will be released after the U.S. markets close on June 16, 2016. The earnings release will be followed by a conference call at 1:30 p.m. PDT on June 16, 2016, to discuss fiscal fourth quarter and year end results.
OCLS: 4.32 (-0.06)
Oculus Innovative Sciences Launches New Ceramax(TM) Skin Barrier Cream in the United States
GlobeNewswire - Tue May 03, 3:05AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ: OCLS, warrants OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced the launch of Ceramax(TM) Skin Barrier Cream, intended to be used as a topical skin care preparation to relieve and to manage the burning and itching associated with various dermatoses including atopic dermatitis, irritant contact dermatitis, radiation dermatitis and other dry skin conditions.
OCLS: 4.32 (-0.06)
Oculus Innovative Sciences to Present at Pioneers 2016 Investor Conference Hosted by Joseph Gunnar & Company in New York City
GlobeNewswire - Thu Apr 28, 4:42AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ: OCLS, warrants OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced that Robert Miller, the company's CFO/COO, will present a corporate overview and business update at the Pioneers 2016 Investor Conference hosted by Joseph Gunnar & Company. The Oculus presentation is scheduled on Thursday, May 5, 2016, at 2:00 pm EDT at the New York Palace Hotel in New York City.
OCLS: 4.32 (-0.06)
Oculus Innovative Sciences to Present at the Third Annual Growth Capital Expo MicroCap Investor Conference in Las Vegas
GlobeNewswire - Wed Apr 27, 3:05AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) (NASDAQ:OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced that Jim Schutz, the company's CEO, will present a corporate overview and business update at the Third Annual Growth Capital Expo MicroCap Investor Conference, to be held on May 3-5, 2016 at Caesars Palace in Las Vegas. The Oculus presentation is scheduled on Wednesday, May 4, 2016, at 10:00 am PDT, with a breakout session to immediately follow.
OCLSW: 0.25 (+0.01), OCLS: 4.32 (-0.06)
Top Stocks on 4/20: Investors Are Considering These on Wednesday April 20th
ACCESSWIRE - Wed Apr 20, 11:57AM CDT
MIAMI, FL / ACCESSWIRE / April 20, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. EBIO, ASM, OCLS, and PBMD have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
PBMD: 0.92 (-0.02), EBIO: 2.48 (+0.52), OCLS: 4.32 (-0.06)
4 Promising Small Cap Stocks That You Need To Know About
ACCESSWIRE - Wed Apr 20, 9:08AM CDT
NEW YORK, NY / ACCESSWIRE / April 20, 2016 / The Stock Expert is issuing a report on four stocks that are trading with heavier than usual volume. OCLS, ONCS, CARA and UNXL are on high volume alert. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
CARA: 5.18 (+0.09), UNXL: 1.41 (+0.10), ONCS: 1.68 (-0.01), OCLS: 4.32 (-0.06)
Oculus Innovative Sciences Receives European Approval to Market Sinudox(TM) Indicated for Use in Nasal Irrigation
GlobeNewswire - Wed Apr 13, 3:05AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) (NASDAQ:OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced the issuance of a new CE Mark in Europe for Microcyn(R)-based Sinudox(TM) solution, a formulation intended for nasal irrigation including the moistening of cuts, abrasions and lacerations located in the nasal cavity.
OCLSW: 0.25 (+0.01), OCLS: 4.32 (-0.06)
Oculus Innovative Sciences Strengthens Intellectual Property Portfolio With Allowance of New Patents for Microcyn(R) Technology
GlobeNewswire - Wed Apr 06, 3:05AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) (NASDAQ:OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced the receipt of several new U.S. and foreign patents relating to its Microcyn Technology hypochlorous acid formulations. Specifically, the company has been granted a U.S. patent, as well as a Canadian patent, for the use of the Oculus Microcyn Technology in the treatment of atopic dermatitis. In addition, two new patents in Mexico and Canada have recently been issued to Oculus relating to other hydrogel formulations and antimicrobial solutions.
OCLSW: 0.25 (+0.01), OCLS: 4.32 (-0.06)
Oculus Innovative Sciences and Lipogrid of Sweden Announce Strategic Collaboration for Topical Dermatology Drug Delivery
GlobeNewswire - Wed Mar 30, 3:05AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) (NASDAQ:OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced it has finalized a strategic collaborative agreement with the Lipogrid Company of Sweden to develop multiple topical drug delivery formulations based upon the company's Lipogrid(R) Technology.
OCLSW: 0.25 (+0.01), OCLS: 4.32 (-0.06)
Oculus Innovative Sciences to Present at the Sidoti Emerging Growth Conference
GlobeNewswire - Thu Mar 24, 3:05AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) (NASDAQ:OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced that Jim Schutz, the company's CEO, will present a corporate overview and business update at the Sidoti Emerging Growth Conference to be held at the Marriott Marquis in Times Square, New York, NY on Thursday, March 31, 2016. The Oculus presentation is scheduled at 1:00pm EDT.
OCLSW: 0.25 (+0.01), OCLS: 4.32 (-0.06)
Oculus Innovative Sciences Announces Multi-Year Licensing Agreement with Manna Pro Products, LLC, for MicrocynAH(R) Animal Healthcare Products
GlobeNewswire - Wed Mar 23, 3:05AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS, warrants OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced a multi-year licensing agreement with Manna Pro Products, LLC, (www.mannapro.com) for the entire family of MicrocynAH(R) animal healthcare products for the North American large animal and farm/home market.
OCLS: 4.32 (-0.06)
Oculus Innovative Sciences Announces Pricing of $3.4 Million Underwritten Public Offering
GlobeNewswire - Fri Mar 18, 7:41AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ: Common Stock - OCLS, Warrants - OCLSW) today announced the pricing of an underwritten public offering of 3,400,000 units, consisting of 3,400,000 shares of common stock, and warrants to purchase an aggregate of 850,000 shares of common stock, at an offering price of $1.00 per share and related warrant. The warrants have an exercise price of $1.00 per share, and are exercisable for a period of three years.
OCLS: 4.32 (-0.06)
Oculus Innovative Sciences to Present at the Roth Capital Partners 28th Annual Conference
GlobeNewswire - Wed Mar 09, 2:05AM CST
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) (warrants OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced that Jim Schutz, the company's CEO, and Robert Miller, Oculus CFO, will jointly present a corporate overview and business update at the Roth Capital Partners 28th Annual Conference to be held at the Ritz Carlton in Laguna Niguel, California. The Oculus presentation is scheduled on Wednesday, March 16, 2016, at 11:30 am PT, with a breakout session to immediately follow.
OCLS: 4.32 (-0.06)
Dermatologists Praise Multiple Benefits of Oculus Innovative Science's Microcyn Technology
ACCESSWIRE - Tue Mar 08, 8:29AM CST
REDONDO BEACH, CA / ACCESSWIRE / March 8, 2016 / Right now there is hypochlorous acid, or HOCl, on the immunological front lines in the bodies of people fighting infections, doing its job as an inorganic bactericidal compound of the innate immune system to destroy a wide spectrum of pathogens. Although still not used as a pharmaceutical drug, the important role of hypochlorous acid in biology is only recently emerging, in addition to its well-documented germicidal properties. For example, research by Serhan Sakarya, MD, et al. shows that HOCl in stable form is an ideal wound care solution with a powerful and rapid killing effect on different types of microorganisms, biofilms and microbicidal effect within the biofilm.
AQXP: 7.05 (+0.08), VNDA: 11.47 (+0.02), VTAE: 10.73 (+0.16), OCLS: 4.32 (-0.06)
Oculus Innovative Sciences Receives European Approval to Market Lasercyn Indicated for Use Following Laser Skin Resurfacing
GlobeNewswire - Thu Mar 03, 2:05AM CST
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) (warrants OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced the issuance of two new CE Marks in Europe for Microcyn(R)-based Lasercyn(TM) solution and hydrogel, formulations intended to moisten and clean skin following procedures such as laser skin resurfacing, surgical wounds, abrasions and for use in the debridement and moistening of cuts, abrasions and minor burns.
OCLS: 4.32 (-0.06)
Oculus Innovative Sciences Announces Record Monthly and Quarterly Prescription Data
GlobeNewswire - Wed Jul 06, 3:05AM CDT
May 2016: Highest Monthly Prescriptions Filled in Oculus' History
OCLS: 4.32 (-0.06)
SECFilings.com Examines Oculus Innovative Sciences' Financial Results and Turnaround Plan
Marketwire Canada - Mon Jun 27, 8:39AM CDT
REDONDO BEACH, CA--(Marketwired - Jun 27, 2016) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, takes a look at Oculus Innovative Sciences' (NASDAQ: OCLS) recently announced fourth quarter and fiscal year 2016 results, as well as the company's ambitious turnaround plan.
OCLS: 4.32 (-0.06)
Oculus Innovative Sciences Announces Reverse Split of Common Stock
GlobeNewswire - Wed Jun 22, 4:05AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ: OCLS, warrants OCLSW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, announced today that a 1-for-5 reverse split of its common stock will be effective after the close of business on Friday, June 24, 2016. The reverse stock split was previously approved by the company's stockholders at the company's special meeting held on June 29, 2015. The company's board of directors approved the implementation of a reverse stock split and determined the appropriate reverse stock split to be a ratio of 1-for-5 on June 2, 2016. The reverse split was not the result of any NASDAQ actions.
OCLS: 4.32 (-0.06)
Oculus Innovative Sciences Announces Financial Results for the Fiscal Year/Fourth Quarter 2016 and Conference Call
GlobeNewswire - Thu Jun 02, 3:05AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ: OCLS, warrants OCLSW), today announced that the financial results for its fiscal year and fourth quarter 2016, ended March 31, 2016, will be released after the U.S. markets close on June 16, 2016. The earnings release will be followed by a conference call at 1:30 p.m. PDT on June 16, 2016, to discuss fiscal fourth quarter and year end results.
OCLS: 4.32 (-0.06)
Oculus Innovative Sciences Launches New Ceramax(TM) Skin Barrier Cream in the United States
GlobeNewswire - Tue May 03, 3:05AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ: OCLS, warrants OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced the launch of Ceramax(TM) Skin Barrier Cream, intended to be used as a topical skin care preparation to relieve and to manage the burning and itching associated with various dermatoses including atopic dermatitis, irritant contact dermatitis, radiation dermatitis and other dry skin conditions.
OCLS: 4.32 (-0.06)
Oculus Innovative Sciences to Present at Pioneers 2016 Investor Conference Hosted by Joseph Gunnar & Company in New York City
GlobeNewswire - Thu Apr 28, 4:42AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ: OCLS, warrants OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced that Robert Miller, the company's CFO/COO, will present a corporate overview and business update at the Pioneers 2016 Investor Conference hosted by Joseph Gunnar & Company. The Oculus presentation is scheduled on Thursday, May 5, 2016, at 2:00 pm EDT at the New York Palace Hotel in New York City.
OCLS: 4.32 (-0.06)
Oculus Innovative Sciences to Present at the Third Annual Growth Capital Expo MicroCap Investor Conference in Las Vegas
GlobeNewswire - Wed Apr 27, 3:05AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) (NASDAQ:OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced that Jim Schutz, the company's CEO, will present a corporate overview and business update at the Third Annual Growth Capital Expo MicroCap Investor Conference, to be held on May 3-5, 2016 at Caesars Palace in Las Vegas. The Oculus presentation is scheduled on Wednesday, May 4, 2016, at 10:00 am PDT, with a breakout session to immediately follow.
OCLSW: 0.25 (+0.01), OCLS: 4.32 (-0.06)
Top Stocks on 4/20: Investors Are Considering These on Wednesday April 20th
ACCESSWIRE - Wed Apr 20, 11:57AM CDT
MIAMI, FL / ACCESSWIRE / April 20, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. EBIO, ASM, OCLS, and PBMD have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
PBMD: 0.92 (-0.02), EBIO: 2.48 (+0.52), OCLS: 4.32 (-0.06)
4 Promising Small Cap Stocks That You Need To Know About
ACCESSWIRE - Wed Apr 20, 9:08AM CDT
NEW YORK, NY / ACCESSWIRE / April 20, 2016 / The Stock Expert is issuing a report on four stocks that are trading with heavier than usual volume. OCLS, ONCS, CARA and UNXL are on high volume alert. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
CARA: 5.18 (+0.09), UNXL: 1.41 (+0.10), ONCS: 1.68 (-0.01), OCLS: 4.32 (-0.06)
Oculus Innovative Sciences Receives European Approval to Market Sinudox(TM) Indicated for Use in Nasal Irrigation
GlobeNewswire - Wed Apr 13, 3:05AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) (NASDAQ:OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced the issuance of a new CE Mark in Europe for Microcyn(R)-based Sinudox(TM) solution, a formulation intended for nasal irrigation including the moistening of cuts, abrasions and lacerations located in the nasal cavity.
OCLSW: 0.25 (+0.01), OCLS: 4.32 (-0.06)
Oculus Innovative Sciences Strengthens Intellectual Property Portfolio With Allowance of New Patents for Microcyn(R) Technology
GlobeNewswire - Wed Apr 06, 3:05AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) (NASDAQ:OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced the receipt of several new U.S. and foreign patents relating to its Microcyn Technology hypochlorous acid formulations. Specifically, the company has been granted a U.S. patent, as well as a Canadian patent, for the use of the Oculus Microcyn Technology in the treatment of atopic dermatitis. In addition, two new patents in Mexico and Canada have recently been issued to Oculus relating to other hydrogel formulations and antimicrobial solutions.
OCLSW: 0.25 (+0.01), OCLS: 4.32 (-0.06)
Oculus Innovative Sciences and Lipogrid of Sweden Announce Strategic Collaboration for Topical Dermatology Drug Delivery
GlobeNewswire - Wed Mar 30, 3:05AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) (NASDAQ:OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced it has finalized a strategic collaborative agreement with the Lipogrid Company of Sweden to develop multiple topical drug delivery formulations based upon the company's Lipogrid(R) Technology.
OCLSW: 0.25 (+0.01), OCLS: 4.32 (-0.06)
Oculus Innovative Sciences to Present at the Sidoti Emerging Growth Conference
GlobeNewswire - Thu Mar 24, 3:05AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) (NASDAQ:OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced that Jim Schutz, the company's CEO, will present a corporate overview and business update at the Sidoti Emerging Growth Conference to be held at the Marriott Marquis in Times Square, New York, NY on Thursday, March 31, 2016. The Oculus presentation is scheduled at 1:00pm EDT.
OCLSW: 0.25 (+0.01), OCLS: 4.32 (-0.06)
Oculus Innovative Sciences Announces Multi-Year Licensing Agreement with Manna Pro Products, LLC, for MicrocynAH(R) Animal Healthcare Products
GlobeNewswire - Wed Mar 23, 3:05AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS, warrants OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced a multi-year licensing agreement with Manna Pro Products, LLC, (www.mannapro.com) for the entire family of MicrocynAH(R) animal healthcare products for the North American large animal and farm/home market.
OCLS: 4.32 (-0.06)
Oculus Innovative Sciences Announces Pricing of $3.4 Million Underwritten Public Offering
GlobeNewswire - Fri Mar 18, 7:41AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ: Common Stock - OCLS, Warrants - OCLSW) today announced the pricing of an underwritten public offering of 3,400,000 units, consisting of 3,400,000 shares of common stock, and warrants to purchase an aggregate of 850,000 shares of common stock, at an offering price of $1.00 per share and related warrant. The warrants have an exercise price of $1.00 per share, and are exercisable for a period of three years.
OCLS: 4.32 (-0.06)
Oculus Innovative Sciences to Present at the Roth Capital Partners 28th Annual Conference
GlobeNewswire - Wed Mar 09, 2:05AM CST
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) (warrants OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced that Jim Schutz, the company's CEO, and Robert Miller, Oculus CFO, will jointly present a corporate overview and business update at the Roth Capital Partners 28th Annual Conference to be held at the Ritz Carlton in Laguna Niguel, California. The Oculus presentation is scheduled on Wednesday, March 16, 2016, at 11:30 am PT, with a breakout session to immediately follow.
OCLS: 4.32 (-0.06)
Dermatologists Praise Multiple Benefits of Oculus Innovative Science's Microcyn Technology
ACCESSWIRE - Tue Mar 08, 8:29AM CST
REDONDO BEACH, CA / ACCESSWIRE / March 8, 2016 / Right now there is hypochlorous acid, or HOCl, on the immunological front lines in the bodies of people fighting infections, doing its job as an inorganic bactericidal compound of the innate immune system to destroy a wide spectrum of pathogens. Although still not used as a pharmaceutical drug, the important role of hypochlorous acid in biology is only recently emerging, in addition to its well-documented germicidal properties. For example, research by Serhan Sakarya, MD, et al. shows that HOCl in stable form is an ideal wound care solution with a powerful and rapid killing effect on different types of microorganisms, biofilms and microbicidal effect within the biofilm.
AQXP: 7.05 (+0.08), VNDA: 11.47 (+0.02), VTAE: 10.73 (+0.16), OCLS: 4.32 (-0.06)
Oculus Innovative Sciences Receives European Approval to Market Lasercyn Indicated for Use Following Laser Skin Resurfacing
GlobeNewswire - Thu Mar 03, 2:05AM CST
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) (warrants OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced the issuance of two new CE Marks in Europe for Microcyn(R)-based Lasercyn(TM) solution and hydrogel, formulations intended to moisten and clean skin following procedures such as laser skin resurfacing, surgical wounds, abrasions and for use in the debridement and moistening of cuts, abrasions and minor burns.
OCLS: 4.32 (-0.06)
